Quinolines and derivatives
Apexbio Technology LLC AM095 1345614-59-6 200mg
AM095 (CAS 1345614-59-6) is an orally bioavailable antagonist targeting the lysophosphatidic acid receptor 1 (LPA1) It selectively inhibits recombinant human and mouse LPA1 receptors with IC50 values of 0 98 M and 0 73 M respectively In cell-based assays AM095 suppresses LPA1-mediated chemotaxis in mouse LPA1/CHO and human melanoma A2058 cells (IC50 values 0 78 M and 0 23 M respectively) In vivo studies demonstrate its ability to prevent LPA-triggered histamine release reduce collagen and protein accumulation and limit inflammatory cell infiltration in mouse pulmonary models AM095 serves as a valuable tool for investigating LPA1-associated pathologies
Medchemexpress LLC AM095 | 1345614-59-6 | 99.7% | 478.47 | 200 MG
AM095 is a selective LPA1 receptor antagonist known for its potent inhibition of LPA-induced calcium flux in human and mouse LPA1-transfected CHO cells. It demonstrates an exceedingly low IC50 for human (0.025 μM) and mouse (0.023 μM) cells, positioning it as a valuable tool for research involving LPA1 receptor pathways.
- Selective LPA1 receptor antagonist.
- Potently inhibits LPA-induced calcium flux.
- Applicable in studies involving human or mouse LPA1-transfected CHO cells.
- Useful for researching LPA1 receptor pathways.
Medchemexpress LLC TL02-59 | 1315330-17-6 | 99.9% | 609.64 | 50 MG
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. It also inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. This compound potently suppresses acute myelogenous leukemia (AML) cell growth.
- Selective Src-family kinase Fgr inhibitor with high potency.
- Inhibits Lyn and Hck.
- Potently suppresses acute myelogenous leukemia (AML) cell growth.
- Induces growth arrest and apoptosis in AML cell lines.
- Eliminates AML cells from spleen and peripheral blood in mouse models.
- Significantly suppresses bone marrow involvement in mouse models.
Medchemexpress LLC TL02-59 | 1315330-17-6 | 99.9% | 609.64 | 25 MG
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. It also inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. This compound potently suppresses the growth of acute myelogenous leukemia (AML) cells.
- Selectively targets the Src-family kinase Fgr with high potency (IC50 of 0.03 nM).
- Also shows inhibitory activity against Lyn (IC50 of 0.1 nM) and Hck (IC50 of 160 nM).
- Potently suppresses acute myelogenous leukemia (AML) cell growth.
- Induces growth arrest and apoptosis of AML cell lines at single-digit nM potency and induces growth arrest in primary AML bone marrow samples.
- Completely eliminates AML cells from the spleen and peripheral blood, and dramatically suppresses bone marrow involvement in a mouse model of AML.
- Has good oral bioavailability with a t1/2 of 5.7 h by i.v injection and 6.5 h by p.o. administration.
Medchemexpress LLC MYF-03-176 | 2857937-59-6 | 99.72% | 410.37 | 25 MG
MYF-03-176 is an orally active inhibitor of TEAD, suppressing TEAD transcriptional activity with an IC50 of 11 nM. It inhibits hippo signaling defective malignant pleural mesothelioma (MPM) cells and demonstrates strong antitumor efficacy in an MPM mouse xenograft model. The IC50 values for TEAD1, TEAD3, and TEAD4 are 47, 32, and 71 nM, respectively.
- Orally active inhibitor of TEAD
- Suppresses TEAD transcriptional activity with an IC50 of 11 nM
- Inhibits hippo signaling defective malignant pleural mesothelioma (MPM) cells
- Demonstrates strong antitumor efficacy in MPM mouse xenograft model